- Home
- GSL vs AMPH Comparison
GSL vs AMPH Comparison
Compare GSL & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- AMPH
- Stock Information
- Founded
- GSL 2007
- AMPH 1996
- Country
- GSL Greece
- AMPH United States
- Employees
- GSL N/A
- AMPH N/A
- Industry
- GSL Marine Transportation
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- GSL Consumer Discretionary
- AMPH Health Care
- Exchange
- GSL Nasdaq
- AMPH Nasdaq
- Market Cap
- GSL 945.2M
- AMPH 1.1B
- IPO Year
- GSL 2006
- AMPH 2014
- Fundamental
- Price
- GSL $27.72
- AMPH $21.95
- Analyst Decision
- GSL Strong Buy
- AMPH Hold
- Analyst Count
- GSL 1
- AMPH 5
- Target Price
- GSL $30.00
- AMPH $38.00
- AVG Volume (30 Days)
- GSL 333.0K
- AMPH 488.9K
- Earning Date
- GSL 08-04-2025
- AMPH 08-06-2025
- Dividend Yield
- GSL 7.58%
- AMPH N/A
- EPS Growth
- GSL 20.64
- AMPH N/A
- EPS
- GSL 10.54
- AMPH 2.77
- Revenue
- GSL $715,232,000.00
- AMPH $730,659,000.00
- Revenue This Year
- GSL $3.22
- AMPH $0.67
- Revenue Next Year
- GSL N/A
- AMPH $5.18
- P/E Ratio
- GSL $2.65
- AMPH $7.94
- Revenue Growth
- GSL 3.83
- AMPH 8.05
- 52 Week Low
- GSL $17.73
- AMPH $21.48
- 52 Week High
- GSL $28.08
- AMPH $53.96
- Technical
- Relative Strength Index (RSI)
- GSL 66.65
- AMPH 31.37
- Support Level
- GSL $26.80
- AMPH $21.48
- Resistance Level
- GSL $28.08
- AMPH $23.77
- Average True Range (ATR)
- GSL 0.57
- AMPH 0.78
- MACD
- GSL 0.06
- AMPH -0.18
- Stochastic Oscillator
- GSL 86.31
- AMPH 13.20
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.